{
    "articleURL": "/wires/reuters/article-12046551/Novo-Nordisk-exec-oral-weight-loss-drug-similar-efficacy-Wegovy.html",
    "content": [
        "COPENHAGEN/LONDON, May 4 (Reuters) - Novo Nordisk expects the oral version of its semaglutide drug to treat obesity to have similar efficacy as its Wegovy injection, with data from a late-stage clinical trial due before the end of June, a senior executive said on Thursday.",
        "Head of development Martin Holst Lange was discussing the trial called OASIS 1 on a call with analysts following the release of better-than-expected first-quarter results by the Danish drugmaker.The company's hugely popular Wegovy therapy is a weekly injection. (Reporting by Nikolaj Skydsgaard in Copenhagen and Maggie Fick in London Writing by Josephine Mason Editing by Mark Potter)"
    ]
}